Vertex defended after setback and Biogen adds another bull at Bernstein; in today’s analyst action
goir/iStock via Getty Images
Vertex defended across the board despite the setback
- Vertex Pharmaceuticals (NASDAQ:VRTX) continues to trade lower with a ~14.0% loss
in the pre-market on its decision to halt the development of VX-864 for alpha-1 antitrypsin…
